BioMarin agrees to buy Alesta Therapeutics for USD 275 million upfront
B
BMRN• BioMarin to acquire Alesta Therapeutics
- BioMarin agreed to buy Alesta Therapeutics for USD 275 million upfront, aiming to add lead asset ALE1 to its pipeline.
- The deal includes up to USD 215 million in milestone payments tied to development and regulatory progress.
- ALE1 is an oral small-molecule candidate for hypophosphatasia, now in a Phase 1/2a trial in healthy volunteers and adults.
- Alesta will spin out non-ALE1 assets before closing, leaving no Alesta employees transferring to BioMarin.
- BioMarin expects to fund the purchase with cash on hand, with a modestly dilutive impact on 2026 results excluding upfront consideration.
XYL
•
BioMarin agrees to buy Alesta Therapeutics for USD 275 million upfront - BMRN News | Rallies
